Government-Enterprise Synergy! Kexing Biopharm Represents Shenzhen Pharmaceutical and Medical Device Industry Overseas Expansion Consortium at Saudi Medical Device Industry Promotion Conference

Article source：Kexing BiopharmOct 17,2025View： 2616

On October 13, the "Saudi Arabia (Riyadh)-China (Shenzhen) Medical Device Industry Promotion Conference," themed "Medical Devices Heading to the Gulf, Cooperation Wins the Future," was grandly held in Riyadh, Saudi Arabia. Guided by the Shenzhen Development and Reform Commission and hosted by the Shenzhen Medical Device Industry Association, the event saw Kexing Biopharm Co., Ltd. (stock code: 688136.SH), as the initiator and executive lead of the Shenzhen Pharmaceutical and Medical Device Industry Overseas Expansion Consortium, attending on behalf of the consortium and completing key cooperation signings at the conference.

Deepening Penetration into Middle East Potential Markets: Government-Enterprise Collaboration Injects Confidence

In recent years, Saudi Arabia has emerged as one of the most promising pharmaceutical and healthcare markets in the Middle East. Through its "Vision 2030" initiative, the Saudi government plans to invest over $65 billion in developing domestic medical infrastructure, restructuring healthcare services and insurance, and launching 21 "health clusters" nationwide. The upgrading of the healthcare system has increasingly expanded local demand for high-end pharmaceuticals and medical devices. According to the Middle East and Africa Pharmaceutical Commercial Insights Report (36th Edition) released by IQVIA in September, pharmaceutical sales in the Saudi market reached $14.6 billion as of the second quarter of 2025, accounting for 37.6% of the total sales in the Middle East and Africa region, making it the fastest-growing country in the area.

From the perspective of China-Saudi cooperation, linkages between the two countries in the healthcare sector have continued to deepen in recent years. Data from the China Pharmaceutical Health Products Import & Export Association shows that bilateral pharmaceutical trade grew from $410 million in 2019 to $620 million in 2023, with a compound annual growth rate of 8.62%; from January to November 2024, the trade volume reached $650 million, and it is expected to maintain a growth trajectory in the future.

At this promotion conference, on-site speeches by leaders from Shenzhen government departments and relevant officials from the Saudi Ministry of Health and Prevention pointed the way forward for cooperation between the two sides, while also demonstrating Shenzhen's support for local medical device enterprises "going global," injecting confidence into the industry's overseas expansion.

Collaborative Overseas Expansion, Sharing Opportunities

As a pioneer in Shenzhen's pharmaceutical and medical device overseas ventures, Kexing Biopharm showcased the company's "Innovation + Internationalization" strategic direction and the strengths of its overseas platform at the conference. It also conveyed the core mission of the Shenzhen Pharmaceutical and Medical Device Industry Overseas Expansion Consortium—"collaborative expansion overseas, sharing opportunities"—attracting significant attention from local Saudi resources.

Leveraging this promotion conference, Kexing Biopharm formally signed an agreement with Pharmaknowl Consulting, a leading local regulatory consulting firm in Saudi Arabia. Established in 2014, Pharmaknowl is a benchmark enterprise in the SFDA (Saudi Food and Drug Authority) regulatory consulting field and has served numerous international pharmaceutical giants. In the future, it has the potential to provide regulatory consulting and local resource docking services for Kexing Biopharm and consortium member enterprises, precisely matching local market demands.

Meanwhile, in Saudi Arabia, Kexing Biopharm currently has several overseas products, including infliximab, bevacizumab, and adalimumab, under registration and approval.

With trends such as population growth and the high incidence of chronic diseases, Saudi Arabia presents vast development potential in affordable and high-quality healthcare services. For Chinese pharmaceutical and medical device enterprises, this market is not only a "blue ocean" for exports but also a strategic pivot for global layout.

In the future, Kexing Biopharm will collaborate with members of the Shenzhen Pharmaceutical and Medical Device Industry Overseas Expansion Consortium and partners to continuously deepen its layout in the Saudi and broader Middle East markets, accelerate the rapid launch of multiple products under registration, and contribute Kexing's strengths to the internationalization of China's pharmaceutical and medical device industry through professional, compliant, and localized operations.